RxSight vs Sight Sciences
RXST and SGHT side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RXST and SGHT compare
Sight Sciences is the larger company, worth 2.7 times as much as RxSight ($597M against $221M).
Sight Sciences grew revenue faster over the last twelve months (16.2% versus −13.2% for RxSight).
Sight Sciences keeps more of each dollar of sales as profit, with a net margin of −32.1% compared with −36.8% at RxSight.
RxSight scores higher on the StockData Score (10 against 5 for Sight Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RXST | SGHT |
|---|---|---|
| Size and price | ||
| Market cap | $221M | $597M |
| Share price | $5.32 | $10.83 |
| Change, 1 year | −46.9% | 40.3% |
| Change, 5 years | −60.7% | −46.3% |
| Beta (5Y) | 1.11 | 1.99 |
| Employees | 461 | 186 |
| StockData Score | ||
| Total score | 10 (better) | 5 |
| Valuation score | 3 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 1 | 1 |
| Health score | 4 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.7× (better) | 6.7× |
| P/B | 0.8× (better) | 12.1× |
| FCF yield | −12.3% | −2.8% (better) |
| Fair value | $20.64 | $4.01 |
| Margin of safety | 74.2% (better) | −170% |
| Growth | ||
| Revenue growth (TTM) | −13.2% | 16.2% (better) |
| Revenue growth, 5Y average | 55.7% (better) | 22.9% |
| Profitability | ||
| Gross margin | 77.5% | 87.7% (better) |
| Operating margin | −43.2% | −29.5% (better) |
| Net margin | −36.8% | −32.1% (better) |
| FCF margin | −21.3% | −19.1% (better) |
| Return on equity | −17.3% (better) | −50.1% |
| Return on invested capital | −82.9% (better) | −134% |
| Financial health | ||
| Debt / equity | 0.00 | 0.96 (better) |
| Interest coverage | −3674.3× | −5.1× (better) |
| Current ratio | 4.07 | 5.04 (better) |
| Altman Z-score | −0.56 | 1.91 (better) |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | −0.90% | – |
| Shareholder yield | −0.90% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 99.6% | 40.2% |
| Held by insiders | 5.4% | 33.1% |
| Insider net buying, 12 months | −$118K (better) | −$2.2M |
| Short interest, % of float | 9.2% | 3.1% |
Go deeper
- RXST stock overview
- RXST income statement
- RXST valuation and score
- SGHT stock overview
- SGHT income statement
- SGHT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.